Abstract
Cancer is the second foremost reason for worldwide death, affecting every country of the globe. However, 70% of cancer-related death was reported from low- and middle-income nations. Delay in the detection and intervention of therapeutic agents in cancer patients also promoted a cancer-related mortality index. Currently, numerous nanomedicines are under development for advancing tumor diagnosis and therapeutic capability. Recently, liquid crystalline nanoparticles (LCNPs) have emerged as an attractive drug delivery system for both intravenous and non-intravenous applications. The widely explored LCNPs for cancer therapy include cubosomes and hexosomes. They have significant advantages over other drug delivery system, which includes, high internal surface area, unique solubilization properties and sustained release of entrapped drug molecules and co-loading of imaging and therapeutic agents in a single system. In this review, we have briefly discussed the advantages of LCNPs, preparation methods, and their multifunctional role in treating various cancers.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
